A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs
Jianzhong Cao, J Craig Forrest, Xuming Zhang, Jianzhong Cao, J Craig Forrest, Xuming Zhang
Abstract
With the recent emergence of Middle East Respiratory Syndrome coronavirus in humans and the outbreak of devastating porcine epidemic diarrhea coronavirus in swine, therapeutic intervention is urgently needed. However, anti-coronavirus drugs currently are not available. In an effort to assist rapid development of anti-coronavirus drugs, here we screened the NIH Clinical Collection in cell culture using a luciferase reporter-expressing recombinant murine coronavirus. Of the 727 compounds screened, 84 were found to have a significant anti-coronavirus effect. Further experiments revealed that 51 compounds blocked virus entry while 19 others inhibited viral replication. Additional validation studies with the top 3 inhibitors (hexachlorophene, nitazoxanide and homoharringtonine) demonstrated robust anti-coronavirus activities (a reduction of 6 to 8log10 in virus titer) with an IC50 ranging from 11nM to 1.2μM. Furthermore, homoharringtonine and hexachlorophene exhibited broad antiviral activity against diverse species of human and animal coronaviruses. Since the NIH Clinical Collection consists of compounds that have already been through clinical trials, these small molecule inhibitors have a great potential for rapid development as anti-coronavirus drugs.
Keywords: Coronavirus; NCC library; Screening; Small molecule.
Copyright © 2014 Elsevier B.V. All rights reserved.
Figures
References
- Al-Tawfiq J.A., Momattin H., Dib J., Memish Z.A. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis. 2014;20:42–46.
- Andruska N., Mao C., Cherian M., Zhang C., Shapiro D.J. Evaluation of a luciferase-based reporter assay as a screen for inhibitors of estrogen-ERalpha-induced proliferation of breast cancer cells. J. Biomol. Screen. 2012;17:921–932.
- Aulner N., Danckaert A., Rouault-Hardoin E., Desrivot J., Helynck O., Commere P.H., Munier-Lehmann H., Spath G.F., Shorte S.L., Milon G., Prina E. High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery. PLoS Negl. Trop. Dis. 2013;7:E2154.
- Barlough J.E., Shacklett B.L. Antiviral studies of feline infectious peritonitis virus in vitro. Vet. Rec. 1994;135:177–179.
- Boukhvalova M.S., Prince G.A., Blanco J.C. Inactivation of respiratory syncytial virus by zinc finger reactive compounds. Virol. J. 2010;7:20.
- Cao J., Zhang X. Comparative in vivo analysis of the nsp15 endoribonuclease of murine, porcine and severe acute respiratory syndrome coronaviruses. Virus Res. 2012;167:247–258.
- Caul E.O., Egglestone S.I. Further studies on human enteric coronaviruses. Arch Virol. 1977;54:107–117.
- CDC, 2004. SARS Basics Fact Sheet.
- Crance J.M., Scaramozzino N., Jouan A., Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 2003;58:73–79.
- Das Sarma J., Fu L., Tsai J.C., Weiss S.R., Lavi E. Demyelination determinants map to the spike glycoprotein gene of coronavirus mouse hepatitis virus. J. Virol. 2000;74:9206–9213.
- Das Sarma J., Scheen E., Seo S.H., Koval M., Weiss S.R. Enhanced green fluorescent protein expression may be used to monitor murine coronavirus spread in vitro and in the mouse central nervous system. J. Neurovirol. 2002;8:381–391.
- De Gans J., Portegies P., Tiessens G., Eeftinck Schattenkerk J.K., Van Boxtel C.J., Van Ketel R.J., Stam J. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS. 1992;6:185–190.
- De Haan C.A., Van G.L., Stoop J.N., Volders H., Rottier P.J. Coronaviruses as vectors: position dependence of foreign gene expression. J. Virol. 2003;77:11312–11323.
- De La Hamaide, S., 2014. Deadly pig virus likely to ease in US by year-end. <>.
- Drosten C., Gunther S., Preiser W., Van Der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1967–1976.
- Efferth T., Romero M.R., Wolf D.G., Stamminger T., Marin J.J., Marschall M. The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 2008;47:804–811.
- Falzarano D. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci. Rep. 2013;3:1686.
- Fan H. The nucleocapsid protein of coronavirus infectious bronchitis virus: crystal structure of its N-terminal domain and multimerization properties. Structure. 2005;13(12):1859–1868.
- Flint M., Mcmullan L.K., Dodd K.A., Bird B.H., Khristova M.L., Nichol S.T., Spiropoulou C.F. Inhibitors of the tick-borne, hemorrhagic fever-associated flaviviruses. Antimicrob. Agents Chemother. 2014;58:3206–3216.
- Fukuoka M., Minakuchi M., Kawaguchi A., Nagata K., Kamatari Y.O., Kuwata K. Structure-based discovery of anti-influenza virus a compounds among medicines. Biochim. Biophys. Acta. 2012;1820:90–95.
- Gough A.H., Chen N., Shun T.Y., Lezon T.R., Boltz R.C., Reese C.E., Wagner J., Vernetti L.A., Grandis J.R., Lee A.V., Stern A.M., Schurdak M.E., Taylor D.L. Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery. PLoS One. 2014;9:E102678.
- Hirano N., Fujiwara K., Hino S., Matumoto M. Replication and plaque formation of mouse hepatitis virus (MHV-2) in mouse cell line DBT culture. Arch. Gesamte Virusforsch. 1974;44:298–302.
- Hsu J.T., Kuo C.J., Hsieh H.P., Wang Y.C., Huang K.K., Lin C.P., Huang P.F., Chen X., Liang P.H. Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. FEBS Lett. 2004;574:116–120.
- Hummel M.A., Locuson C.W., Gannett P.M., Rock D.A., Mosher C.M., Rettie A.E., Tracy T.S. CYP2C9 genotype-dependent effects on in vitro drug–drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol. Pharmacol. 2005;68:644–651.
- Jayaram H. X-ray structures of the N- and C-terminal domains of a coronavirus nucleocapsid protein: implications for nucleocapsid formation. J. Virol. 2006;80(13):6612–6620.
- Keeffe E.B., Rossignol J.F. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J. Gastroenterol. 2009;15:1805–1808.
- Kim S.M., Park J.H., Lee K.N., Kim S.K., Ko Y.J., Lee H.S., Cho I.S. Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-alpha and antiviral agents. Antiviral Res. 2012;96:213–220.
- Korba B.E., Montero A.B., Farrar K., Gaye K., Mukerjee S., Ayers M.S., Rossignol J.F. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 2008;77:56–63.
- Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., Derisi J., Yang J.Y., Cox N., Hughes J.M., Leduc J.W., Bellini W.J., Anderson L.J. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1953–1966.
- Lim P.L., Lee T.H., Rowe E.K. Middle East respiratory syndrome coronavirus (MERS CoV): update 2013. Curr. Infect. Dis. Rep. 2013;15:295–298.
- Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R., Mayo M., Mcdonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., Roper R.L. The genome sequence of the SARS-associated coronavirus. Science. 2003;300:1399–1404.
- Mitka M. Deadly MERS coronavirus not yet a global concern. JAMA. 2013;310:569.
- Morgenstern B., Michaelis M., Baer P.C., Doerr H.W., Cinatl J., Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem. Biophys. Res. Commun. 2005;326:905–908.
- Morrey J.D., Smee D.F., Sidwell R.W., Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res. 2002;55:107–116.
- Phillips J.J., Chua M.M., Lavi E., Weiss S.R. Pathogenesis of chimeric MHV4/MHV-A59 recombinant viruses: the murine coronavirus spike protein is a major determinant of neurovirulence. J. Virol. 1999;73:7752–7760.
- Pyrc K., Bosch B.J., Berkhout B., Jebbink M.F., Dijkman R., Rottier P., Van Der Hoek L. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob. Agents Chemother. 2006;50:2000–2008.
- Rachidi N., Taly J.F., Durieu E., Leclercq O., Aulner N., Prina E., Pescher P., Notredame C., Meijer L., Spath G.F. Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection. Antimicrob. Agents Chemother. 2014;58:1501–1515.
- Reinders M.K., Van Roon E.N., Jansen T.L., Delsing J., Griep E.N., Hoekstra M., Van De Laar M.A., Brouwers J.R. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann. Rheum. Dis. 2009;68:51–56.
- Resta S., Luby J.P., Rosenfeld C.R., Siegel J.D. Isolation and propagation of a human enteric coronavirus. Science. 1985;229:978–981.
- Romero M.R., Serrano M.A., Efferth T., Alvarez M., Marin J.J. Effect of cantharidin, cephalotaxine and homoharringtonine on “in vitro” models of hepatitis B virus (HBV) and bovine viral diarrhoea virus (BVDV) replication. Planta Med. 2007;73:552–558.
- Rossignol J.F., La F.S., Chiappa L., Ciucci A., Santoro M.G. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. 2009;284:29798–29808.
- Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., Derisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., Mccaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300:1394–1399.
- Saijo M., Morikawa S., Fukushi S., Mizutani T., Hasegawa H., Nagata N., Iwata N., Kurane I. Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus. Antiviral Res. 2005;66:159–163.
- Sattar S.A., Raphael R.A., Lochnan H., Springthorpe V.S. Rotavirus inactivation by chemical disinfectants and antiseptics used in hospitals. Can. J. Microbiol. 1983;29:1464–1469.
- Seguin S.P., Ireland A.W., Gupta T., Wright C.M., Miyata Y., Wipf P., Pipas J.M., Gestwicki J.E., Brodsky J.L. A screen for modulators of large T antigen’s ATPase activity uncovers novel inhibitors of simian virus 40 and BK virus replication. Antiviral Res. 2012;96:70–81.
- Shi Z., Wei J., Deng X., Li S., Qiu Y., Shao D., Li B., Zhang K., Xue F., Wang X., Ma Z. Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model. Virol. J. 2014;11:10.
- Siddiq D.M., Koo H.L., Adachi J.A., Viola G.M. Norovirus gastroenteritis successfully treated with nitazoxanide. J. Infect. 2011;63:394–397.
- Sinclair D.S., Fox I.H. The pharmacology of hypouricemic effect of benzbromarone. J. Rheumatol. 1975;2:437–445.
- Sorensen M.D., Sorensen B., Gonzalez-Dosal R., Melchjorsen C.J., Weibel J., Wang J., Jun C.W., Huanming Y., Kristensen P. Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals. Ann. N. Y. Acad. Sci. 2006;1067:500–505.
- Stevenson G.W., Hoang H., Schwartz K.J., Burrough E.R., Sun D., Madson D., Cooper V.L., Pillatzki A., Gauger P., Schmitt B.J., Koster L.G., Killian M.L., Yoon K.J. Emergence of porcine epidemic diarrhea virus in the United States: clinical signs, lesions, and viral genomic sequences. J. Vet. Diagn. Invest. 2013;25:649–654.
- Tebas P., Powderly W.G. Nelfinavir mesylate. Expert Opin. Pharmacother. 2000;1:1429–1440.
- Walson J.L., Otieno P.A., Mbuchi M., Richardson B.A., Lohman-Payne B., Macharia S.W., Overbaugh J., Berkley J., Sanders E.J., Chung M.H., John-Stewart G.C. Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS. 2008;22:1601–1609.
- Wang L., Byrum B., Zhang Y. New variant of porcine epidemic diarrhea virus, United States, 2014. Emerg. Infect. Dis. 2014;20:917–919.
- White A.C., Jr. Nitazoxanide: an important advance in anti-parasitic therapy. Am. J. Trop. Med. Hyg. 2003;68:382–383.
- WHO, 2014. WHO MERS-CoV. <>.
- Zhang X.D. A pair of new statistical parameters for quality control in RNA interference high-throughput screening assays. Genomics. 2007;89:552–561.
- Zhang X.M., Herbst W., Kousoulas K.G., Storz J. Biological and genetic characterization of a hemagglutinating coronavirus isolated from a diarrhoeic child. J. Med. Virol. 1994;44:152–161.
- Zhang X.M., Kousoulas K.G., Storz J. Comparison of the nucleotide and deduced amino acid sequences of the S genes specified by virulent and avirulent strains of bovine coronaviruses. Virology. 1991;183:397–404.
- Zhu H., Yu D., Zhang X. The spike protein of murine coronavirus regulates viral genome transport from the cell surface to the endoplasmic reticulum during infection. J. Virol. 2009;83:10653–10663.
Source: PubMed